Future studies utilizing this murine model should investigate infection with clinical CF S. aureus isolates, which have recently been reported to withstand killing by higher concentrations of hypochlorous acid and have a potential in vivo fitness advantage compared to non-CF strains, and therefore may have different responses to therapeutic treatment with a MEK1/2 inhibitor compound (Jennings et al., 2023). Here, MAP2K1 is linked to cystic fibrosis.